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Abstract:  Recent  genome-wide  analysis  has  demonstrated  that  somatic  mutations  in 
ARID1A (BAF250) are the most common molecular genetic changes in ovarian clear cell 
carcinoma (OCCC). ARID1A mutations, which occur in approximately half of OCCC cases, 
lead to deletion of the encoded protein and inactivation of the putative tumor suppressor. In 
this  study,  we  determined  the  significance  of  loss  of  ARID1A  immunoreactivity  with 
respect  to  several  clinicopathological  features  in  a  total  of  149  OCCCs.  First,  we 
demonstrated  that  ARID1A  immunohistochemistry  showed  concordance  with  the 
mutational status in 91% of cases with 100% sensitivity and 66% specificity. Specifically, 
among  12  OCCC  cases  for  which  ARIDA  mutational  status  was  known,  ARIDIA 
immunoreactivity was undetectable in all 9 cases harboring ARID1A mutations and was 
undetectable in one of 3 cases with wild-type ARID1A. With respect to the entire cohort, 
ARID1A immunoreactivity was undetectable in 88 (59%) of 149 OCCCs. There was no 
significant  difference  between  ARID1A  negative  and  positive  cases  in  terms  of 
histopathologic features, age, clinical stage, or overall survival. In conclusion, this study 
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provides further evidence that mutations in ARID1A resulted in loss of ARID1A protein 
expression in OCCC, although no significant differences between ARID1A positive and 
negative cases were observed with respect to any clinicopathological features examined. 
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1. Introduction  
Recent  genome-wide  sequencing  analyses  of  all  exons  and  transcriptome  in  ovarian  clear  cell 
carcinomas (OCCC) have identified somatic mutations of ARID1A (the AT-rich interactive domain 
1A), also known as BAF250, in approximately half of OCCC cases [1,2]. ARID1A is located within 
chromosome 1p36, a region frequently deleted in a variety of human neoplastic diseases including 
OCCC [3]. ARID1A encodes a large nuclear protein that interacts with several other proteins including 
the core ATPase, either BRG or BRM, to form a SWI/SNF chromatin remodeling complex  [4,5]. 
While BRG or BRM is directly responsible for moving the SWI/SNF complex along the DNA strands 
in an ATP-dependent process, it is the non-catalytic subunit, in this case ARID1A, that has the ability 
to  modulate  target  specificity  and  ATPase  activity.  It  has  been  demonstrated  that  the  chromatin 
remodeling  activity  of  SWI/SNF  plays  an  essential  role  in  regulating  gene  expression  [6]  and  is 
important in development and cellular differentiation as well as in tumor suppression [5,7,8]. Indeed, 
the  frequent  somatic  mutations  in  ARID1A  in  OCCC  suggest  a  major  role  for  ARID1A  in  the 
pathogenesis of OCCC. The majority of ARID1A mutations in OCCC belong to either insertion or 
deletion  of  base  pairs,  leading  to  frame  shifts  and  ending  in  stop  codons.  As  a  result,  ARID1A 
mutations  typically  generate  truncated  proteins  that  are  highly  prone  to  degradation  (Guan, 
unpublished result), a characteristic feature of classical tumor suppressors.  
Inactivating mutations in tumor suppressors could participate, not only in tumor initiation, but also 
in tumor progression and response to therapy. In the current study, we asked whether loss of ARID1A 
protein expression had clinical significance in patients with OCCCs and whether loss of ARID1A 
correlated with any histopathological features in those cases. We first correlated the ARID1A mutation 
status and loss of ARID1A expression in selected cases to demonstrate the sensitivity and specificity of 
applying ARID1A immunoreactivity as a surrogate marker for ARID1A mutations. We then performed 
immunohistochemistry to assess ARID1A expression patterns on paraffin sections from a total of 149 
cases of ovarian clear cell carcinoma with well annotated clinical follow up information. The findings 
from this report provide further evidence to characterize the biological and clinical significance of loss 
of ARID1A expression in OCCC. 
2. Results and Discussion 
2.1. Results 
We  employed  immunohistochemistry  to  evaluate  the  expression  of  ARID1A  in  OCCC  tissues. 
Results  of  ARID1A  immunohistochemistry  in  OCCCs  are  summarized  in  Table  1.  ARID1A 
immunoreactivity  was  detected  exclusively  in  nuclei  of  cells,  and  when  protein  expression  was Int. J. Mol. Sci. 2010, 11                       
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observed, it was always seen in a diffuse pattern. Positive immunoreactivity of ARID1A was recorded 
in 61 (41%) of 149 cases. Specifically, 88 (59%), 36 (24%), and 25 (17%) of 149 cases had a staining 
intensity  score  of  0,  1+,  and  2+,  respectively.  Histological  features  in  representative  cases  with 
different  ARID1A  immunostaining  intensities  and  their  mutational  status  are  shown  in  Figure  1.  
Intra-tumoral non-neoplastic mesenchymal cells were usually strongly positive for ARID1A, and they 
served as positive controls, especially for negative cases.  
In order to determine the biological significance of ARID1A expression in OCCC, we also analyzed 
ARID1A immunoreactivity in normal endometrium and adnexal endometriosis because OCCC most 
likely arises from endometrial glandular epithelium (Table 2). The results are shown in Table 2. All 
adnexal endometriosis cases (5/5) showed diffuse ARID1A immunoreactivity. Two cases showed 2+ 
positivity and 3 cases showed 1+ positivity. Normal endometrial glands also expressed ARID1A in all 
cases (38/38) regardless of menstrual phase. As compared to normal endometrium and endometriosis, 
OCCC showed a significantly higher frequency of a staining score equal to 0 (p < 0.0001, Fisher’s 
exact test). Therefore, we defined a staining score of 0 as a loss of ARID1A expression. 
To determine if loss of ARID1A expression was associated with inactivating mutations of ARID1A, 
we correlated mutational status and immunoreactivity in 12 representative OCCCs. All OCCCs that 
harbored ARID1A mutations exhibited negative immunoreactivity, suggesting that ARID1A mutation 
resulted in loss of protein expression (Table 3). Among wild-type OCCCs (no ARID1A mutations),  
2  of  3  cases  exhibited  diffuse  ARID1A  immunoreactivity;  however,  one  case  of  OCCC  with  no 
ARID1A mutations demonstrated loss of ARID1A protein expression (score = 0).  
Next,  we  assessed  the  potential  effects  of  loss  of  ARID1A  expression  on  clinicopathological 
features  of  OCCCs  by  correlating  ARID1A  expression  with  several  clinical  and  pathological 
characteristics of OCCC (Table 4). We found that there was no significant association of ARID1A 
expression and age at disease presentation, clinical stage, metastasis in lymph node, or histological 
features (p > 0.05). ARID1A immunoreactivity was not significantly correlated with adenofibromatous 
versus cystic OCCC (p = 0.266), although there was a trend toward the association of loss of ARID1A 
expression with cystic lesions among OCCCs with a substantial adenofibromatous component (≥10%) 
(Table 4). Similarly, there was no significant difference between ARID1A expression and structural 
patterns  including  papillary,  tubulocystic,  and  solid  features  (p  =  0.957)  or  between  ARID1A 
immunoreactivity and nuclear grade (p = 0.232). Kaplan-Meier analyses were performed to determine 
if there was a correlation between ARID1A expression and clinical outcome. No significant difference 
in survival was found between ARID1A positive and negative cases (P = 0.97) (Figure 2).  
2.2. Discussion 
Genome wide mutational analysis has identified ARID1A as the most commonly mutated gene in 
OCCC. Inactivation mutations of ARID1A resulted in loss of expression in tumors and loss of tumor 
suppressor function of ARID1A. In this report, we asked if loss of ARID1A expression correlated with 
morphological  features  or  had  an  influence  on  disease  aggressiveness  and  treatment  response  in 
OCCC. Although a recent study of 132 OCCCs demonstrated a lack of significant correlation between 
absence  of  ARID1A  expression  and  overall  survival  in  OCCC  patients  [2],  the  current  study 
represented  a  detailed  correlation  study  of  loss  of  ARID1A  expression  and  a  variety  of Int. J. Mol. Sci. 2010, 11                       
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clinicopathological features which have not yet been studied. Our results have several implications 
regarding the potential role of ARID1A mutations in the pathogenesis of OCCC.  
The observation that 59% of OCCCs exhibited an ARID1A intensity score of 0 is similar to the 
frequency (57%) of ARID1A mutation among OCCCs in a previous report that used purified OCCC 
samples for mutational analysis [1]. The percentage of cases exhibiting loss of ARID1A expression in 
the current cohort is slightly higher than the 42% reported in a previous cohort [2]. Nevertheless, both 
studies  indicate  that  loss  of  ARID1A  protein  expression  is  common  among  OCCCs.  One  of  the 
explanations for the lack of correlation of ARID1A expression and clinical stage and overall survival is 
that the loss of ARID1A expression occurs very early during tumor development of OCCC. Normally, 
ARID1A protein may act  as  a  gatekeeper to  prevent  excessive  cellular proliferation and suppress 
tumorigenesis. It has been shown, for example, that ARID1A is essential for normal cell cycle arrest 
[9]  and  the  transforming  potential  of  antisense  expression  of  ARID1A  has  been  demonstrated  in 
NIH3T3 cells [10]. As well, ARID1A expression was lost in atypical endometriosis, which represents 
precursor lesions of OCCC [2]. Therefore, loss of ARID1A protein expression may not be as critical to 
tumor progression as to tumor initiation, which would explain why there was no difference in terms of 
clinical stage and treatment outcome between cases with and without ARID1A expression.  
One may ask whether pathogenesis differs between OCCCs with and without ARID1A expression. 
It has been proposed, based on a recent comprehensive clinicopathological study, that OCCC develops 
from two distinct morphological pathways [11]. One pathway derives from a cyst and the other from 
an  adenofibroma.  Classification  of  OCCCs  into  cystic  and  adenofibromatous  groups  reveals 
differences in several clinicopathological features associated with each morphological group, including 
frequency  in  association  with  endometriosis,  stage  distribution,  histologic  patterns,  and  clinical 
outcome. Although there was a trend of loss of ARID1A expression and cystic OCCC, the correlation 
was  not  significant.  Similarly,  based  on  the  ARID1A  mutational  status  in  38  previously  analyzed 
OCCCs [1], we found there was no significant correlation between ARID1A mutations and either cystic 
or  adenofibromatous  features  (p  =  0.438;  Fisher  Exact  test).  Further  studies  should  focus  on 
determining the molecular difference between OCCCs with and without ARID1A expression using 
genome-wide  approaches.  Finally,  those  OCCCs  with  ARID1A  expression  may  utilize  other 
mechanisms such as genetic deletion or loss of expression of the ARID1A binding partner, BRG1, to 
inactivate the ARID1A-BRG1 chromatin remodeling complex.  
Table 1. ARID1A expression in ovarian clear cell carcinoma. 
Immunostaining intensity score  Number of cases 
0  88 
1+  36 
2+  25 
Total  149 
 
Negative, n = 88 
Positive, n = 61 Int. J. Mol. Sci. 2010, 11                       
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Table 2. ARID1A expression in adnexal endometriosis and endometrial glands.  
Staining 
intensity 
score 
Adnexal 
endometriosis 
Endometrium 
Proliferative 
Endometrium 
Secretory 
Endometrium 
Menstrual 
Endometrium 
Gestational 
0  0  0  0  0  0 
1+  3  0  2  2  6 
2+  2  11  9  2  6 
Total  5  11  11  4  12 
Table 3. Correlation of ARID1A immunoreactivity and mutation status in ovarian clear 
cell carcinoma.  
  Mutant  Wild-type 
IHC+  0  2 
IHC-  9  1 
p = 0.0073 
Table 4. Correlation of ARID1A expression with clinicopathological features of ovarian 
clear cell carcinomas. 
  ARID1A expression  P 
    Positive  Negative 
Age (n = 89)* 
≥50 years 
<50 years 
 
18 
13 
 
40 
18 
 
0.30 
 
Stage (n = 121) 
 I, II 
 III, IV 
 
38 
13 
 
52 
18 
 
0.98 
Nuclear atypia (n = 89)*  
 Mild  
 Moderate 
 Severe  
 
5 
21 
5 
 
18  
35 
 5  
 
0.23  
 
Structural pattern (n = 89)*  
  Papillary  
  Tubulo-cystic 
  Solid 
 
14 
10 
7  
 
27 
17 
14  
 
0.96 
 
Adenofibromatous versus cystic (n = 89)*  
Macroscopically cystic and no AF (0–9%) 
Macroscopically non-cystic with AF (≥10%) 
Macroscopically non-cystic with no AF (0–9%) OR 
Macroscopically cystic with AF (≥10%) 
 
14 
5 
12  
 
 
38 
3 
17  
 
 
 
 
Adenofibromatous versus cystic (n = 89)*  
Macroscopically cystic 
Macroscopically non-cystic with AF(≥1%) 
 
20 
6 
 
46 
7 
 
0.27 
 
 
0.044 
  0.096 
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Figure 1. ARID immunoreactivity in three representative OCCCs which differ with respect 
to  ARID1A  mutational  status.  The  OCCC  with  wild-type  ARID1A  shows  intense  and 
diffuse nuclear immunoreactivity in both tumor and stromal cells. In contrast, the other two 
cases, both with insertion mutations, exhibit undetectable ARID1A immunoreactivity while 
the stromal cells are positive, serving as internal positive controls.  
 
Figure  2.  Kaplan-Meier  analysis  demonstrates  lack  of  significance  between  ARID1A 
immunoreactivity and overall survival in multivariate analysis.  
 
3. Experimental Section  
3.1. Tissue Materials  
Formalin-fixed  and  paraffin-embedded  OCCC  tissues  were  obtained  from  the  Department  of 
Pathology at the University of Tokyo Hospital (89 cases) and the Department of Pathology at the 
National Taiwan University Hospital (60 cases). All tumors were primary and were retrieved from the 
archives  of  each  institution.  Hematoxylin  and  eosin  stained  slides  were  reviewed  to  confirm  the 
diagnosis using the most recent criteria of the World Health Organization. The tumor samples were 
arranged  in  tissue  microarrays  to  facilitate  immunohistochemistry.  At  least  2  cores  (3  mm)  were 
punched out for each case, and immunoreactivity of ARID1A was evaluated on those available cores. 
Tissue collection was in accordance with institutional guidelines.  Int. J. Mol. Sci. 2010, 11                       
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Clinical information including demographics, age at diagnosis, clinical stage based on International 
Federation of Gynecology and Obstetrics (FIGO), and survival time after treatment were obtained for 
patients from whom records were available for review. Correlations of ARID1A expression with the 
following clinical variables were evaluated: age, stage of carcinoma (stage I/II vs. stage III/IV), and 
retroperitoneal  lymph  node metastasis. Specifically, clinical  stage  was  assessable in  121 cases for 
which the staging procedures were complete; the remaining 28 cases were not included in analysis due 
to  either  incomplete  surgical  procedures  or  missing  data.  Results  of  retroperitoneal  lymph  node 
dissection were obtainable in 70 cases. Follow-up information included overall survival and cancer-
related death. The follow-up period was calculated from the date of surgery to the date of death or last 
clinical evaluation. The mean follow-up interval was 59.9 months (range 1–196 months). In this study, 
the cases  with  adenofibromatous  features  were  defined as  those non-cystic lesions  containing any 
percentage  of  adenofibromatous  component;  cystic  cases  were  defined  as  those  with  a  grossly 
identifiable  cyst.  The  distinction  among  different  structural  patterns  (tubulo-cystic,  solid,  and 
papillary) was based on the predominant component in a given specimen. Nuclear grades were made 
according to their relative nuclear atypia and were classified as mild, moderate, or severe atypia.  
3.2. Immunohistochemistry 
Tissue sections (4 μm) were prepared from the tissue microarray blocks. In addition, whole sections 
were used for analysis of tumors in the correlation study of ARID1A mutation and expression. Antigen 
retrieval was performed on deparaffinized sections by autoclaving them at 120 C in a citrate buffer 
(pH 6.0) for 5 minutes. Slides were placed onto a Ventana Benchmark
® XT autostainer (Ventana 
Medical Systems Inc, Tucson, AZ) and immunohistochemical reactions were performed according to 
standard techniques of the autostainer. A commercially available monoclonal anti-ARID1A antibody, 
clone 3H2 (Sigma-Aldrich), was used at an optimal dilution of 1:25.  
Because the distribution of ARID1A immunoreactivity was almost always homogenous within a 
given tumor, we used intensity scores of 0 (undetectable), 1+ (weakly positive), or 2+ (strong positive) 
to evaluate ARID1A immunoreactivity. A positive reaction was defined as discrete localization of the 
chromogen in the nuclei. The tissues were scored in a blinded fashion without knowledge of clinical 
information. Because we were focused on the loss of expression, we divided the cases into two groups: 
those scored as  1+ or 2+, and those scored as  0. To correlate the  ARID1A mutational  status  and 
immunoreactivity, we selected 12 clear cell carcinomas for which the ARID1A mutational status was 
known from our previous study [1]. 
3.3. Statistical Analysis 
Statistical analysis was performed using the Fisher’s exact test. Overall survival of OCCC cases 
was  calculated using the Kaplan-Meier method, and statistical  analyses were performed using  the  
log-rank test. Statistical analyses were performed with StatView 5.0 software (SAS Institute, Cary, 
NC, USA) and P < 0.05 was considered statistically significant. Int. J. Mol. Sci. 2010, 11                       
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4. Conclusion 
In conclusion, results from this study provided cogent evidence that ARID1A immunoreactivity did 
not correlate with any clinicopathological features examined in OCCC. It is likely that loss of ARID1A 
protein expression is not as important for tumor progression or response to treatment as it is for tumor 
initiation.  Future  studies  will  be  required  to  define  the  molecular  mechanisms  by  which  loss  of 
ARID1A expression contributes to tumor development in OCCC.  
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